Iris Ruth Hartley

Iris Ruth Hartley

Auto-generated profile, based on publicly available information

Iris Ruth Hartley

National Institute of Dental and Craniofacial Research, NIH

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
KRKelly L Roszko
Kelly L Roszko
LSLyndsay M Stapleton Smith
Lyndsay M Stapleton Smith
ASAnanth V Sridhar
Ananth V Sridhar
MRMary Scott Roberts
Mary Scott Roberts
IHIris R Hartley
Iris R Hartley
ENEdward F Nemeth
Edward F Nemeth
Autosomal dominant hypocalcemia type 1 (ADH1) is a rare form of hypoparathyroidism due to activating variants of the calcium-sensing receptor gene (CASR). Inherited or de novo activating variants of the CASR alter the set point for extracellular calcium, resulting in inadequate parathyroid hormone (PTH) secretion and inappropriate renal calcium excretion leading to hypocalcemia and hypercalciuria. Conventional therapy includes calcium and activated vitamin D, which can worsen hypercalciuria, resulting in renal complications. A systematic literature review, using published reports from 1994 to 2021, was conducted to catalog CASR variants, to define the ADH1 clinical spectrum, and to determine the effect of treatment on patients with ADH1. There were 113 unique CASR variants reported, with a general lack of genotype/phenotype correlation. Clinical data were available in 191 patients; 27% lacked symptoms, 32% had mild/moderate symptoms, and 41% had severe symptoms. Seizures, the most frequent clinical presentation, occurred in 39% of patients. In patients with blood and urine chemistries available at the time of diagnosis (n = 91), hypocalcemia (99%), hyperphosphatemia (59%), low PTH levels (57%), and hypercalciuria (34%) were observed. Blood calcium levels were significantly lower in patients with severe symptoms compared with asymptomatic patients (6.8 ± 0.7 versus 7.6 ± 0.7 mg/dL [mean ± SD]; p < 0.0001), and the age of presentation was significantly lower in severely symptomatic patients (9.1 ± 15.0 versus 19.3 ± 19.4 years; p < 0.01). Assessments for complications including nephrocalcinosis, nephrolithiasis, renal impairment, and brain calcifications in 57 patients on conventional therapy showed that 75% had at least one complication. Hypercalciuria was associated with nephrocalcinosis, nephrolithiasis, renal impairment, or brain calcifications (odds ratio [OR] = 9.3; 95% confidence interval [CI] 2.4–37.2; p < 0.01). In 27 patients with urine calcium measures before and after starting conventional therapy, the incidence of hypercalciuria increased by 91% (p < 0.05) after therapy initiation. ADH1 is a condition often associated with severe symptomatology at presentation with an increase in the risk of renal complications after initiation of conventional therapy. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

28 September 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
RGRachel I. Gafni
Rachel I. Gafni
IHIris R. Hartley
Iris R. Hartley
KRKelly L. Roszko
Kelly L. Roszko
ENEdward F. Nemeth
Edward F. Nemeth
KPKaren A. Pozo
Karen A. Pozo
MCMichael T. Collins
Michael T. Collins

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
IHIris R. Hartley
Iris R. Hartley
RGRachel I. Gafni
Rachel I. Gafni
KRKelly L. Roszko
Kelly L. Roszko
SBSydney M. Brown
Sydney M. Brown
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
PFPablo Florenzano
Pablo Florenzano

9 September 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
IHIris R. Hartley
Iris R. Hartley
CMCarole B. Miller
Carole B. Miller
GPGeorgios Z. Papadakis
Georgios Z. Papadakis
CBClemens Bergwitz
Clemens Bergwitz
JRJaydira del Rivero
Jaydira del Rivero
MCMichael T. Collins
Michael T. Collins
This letter describes the treatment of a patient with tumor-induced osteomalacia due to a phosphaturic mesenchymal tumor. The discovery of FN1FGFR1 fusion genes in such tumors has led to the identification of fibroblast growth factor receptor 1 as a potential therapeutic target. Here, the use of infigratinib, an FGFR1–3 tyrosine kinase inhibitor, decreased bone lesions.

22 July 2022 in JBMR Plus
Verified
Journal Article
Open access
IHIris R. Hartley
Iris R. Hartley
KRKelly L. Roszko
Kelly L. Roszko
XLXiaobai Li
Xiaobai Li
KPKaren Pozo
Karen Pozo
JSJamie Streit
Jamie Streit
RGRachel I. Gafni
Rachel I. Gafni
Tumor‐induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by ectopic production of fibroblast growth factor 23 (FGF23) by phosphaturic mesenchymal tumors (PMTs). Acting on renal tubule cells, excess FGF23 decreases phosphate reabsorption and 1,25‐dihydroxy‐vitamin D (1,25D) production, leading to hypophosphatemia, impaired bone mineralization, pain, and fractures. Fibronectin 1‐fibroblast growth factor receptor 1 (FN1‐FGFR1) gene fusions have been identified as possible drivers in up to 40% of resected PMTs. Based on the presumptive role of FGFR1 signaling by chimeric FN1‐FGFR1 proteins, the effectiveness of infigratinib, a FGFR1‐3 tyrosine kinase inhibitor, was studied in an open‐label, single‐center, phase 2 trial. The primary endpoint was persistent normalization of blood phosphate and FGF23 after discontinuation. Four adults with TIO (two nonlocalized, two nonresectable PMTs) were treated with daily infigratinib for up to 24 weeks. All patients had a favorable biochemical response that included reduction in intact FGF23, and normalization of blood phosphate and 1,25D. However, these effects disappeared after drug discontinuation with biochemistries returning to baseline; no patients entered biochemical remission. In the two patients with identifiable tumors, 68Gallium (68Ga)‐DOTATATE and 18Fluoride (18F)‐Fluorodeoxyglucose (FDG) PET/CT scans showed a decrease in PMT activity without change in tumor size. Patients experienced mild to moderate, treatment‐related, dose‐limiting adverse events (AEs), but no serious AEs. Three patients had dose interruptions due to AEs; one patient continued on a low dose for the entire 24 weeks and one patient stopped therapy at 17 weeks due to an AE. The study closed early due to a failure to meet the primary endpoint and a higher‐than‐expected incidence of ocular AEs. Infigratinib treatment lowered FGF23, increased blood phosphate, and suppressed PMT activity, confirming the role of FGFR signaling in PMT pathogenesis. However, treatment‐related AEs at efficacy doses and disease persistence on discontinuation support restricting the use of infigratinib to patients with life‐limiting metastatic PMTs. © 2022 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
DODiana Ovejero
Diana Ovejero
IHIris R Hartley
Iris R Hartley
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
ETElizabeth Theng
Elizabeth Theng
XLXiaobai Li
Xiaobai Li
MCMichael T Collins
Michael T Collins
Parathormone (PTH) and fibroblast growth factor 23 (FGF23) both influence blood phosphate levels by regulating urinary phosphate reabsorption. Clinical data suggest that adequate renal phosphate handling requires the presence of both FGF23 and PTH, but robust evidence is lacking. To investigate whether the phosphaturic effects of PTH and FGF23 are interdependent, 11 patients with hypoparathyroidism, which features high blood phosphate in spite of concomitant FGF23 elevation, and one patient with hyperphosphatemic familial tumoral calcinosis (HFTC), characterized by deficient intact FGF23 action and resulting hyperphosphatemia, were treated with synthetic human PTH 1-34 (hPTH 1-34). Biochemical parameters including blood phosphate, calcium, intact FGF23 (iFGF23), nephrogenic cAMP, 1,25(OH)2 vitamin D (1,25D) and tubular reabsorption of phosphate (TRP), were measured at baseline, and after hPTH 1-34 treatment. In patients with hypoparathyroidism, administration of hPTH 1-34 increased nephrogenic cAMP which resulted in serum phosphate normalization followed by a significant decrease in iFGF23. TRP initially decreased and returned to baseline. In the patient with HFTC, hPTH 1-34 administration also increased nephrogenic cAMP, but this did not produce changes in phosphate or TRP. No changes in calcium were observed in any of the studied patients, although prolonged hPTH 1-34 treatment did induce supraphysiologic 1,25D levels in the patient with HFTC. Our results indicate that PTH and FGF23 effects on phosphate regulation are interdependent and both are required to adequately regulate renal phosphate handling.